The BMJ reports the study, starting in early 2027, will look at the weight loss drug's effect on contact with the justice system and other social outcomes.
Recap by typeshit. Full story at The BMJ.
Topol points to work suggesting the body's own GLP-1 family peptides help reduce inflammation in the gut. Details are thin, so tap through for the study.
Medscape explores whether GLP-1 medicines might help keep people with schizophrenia out of the hospital. Tap through for the evidence behind the idea.
The weight loss drug class started with a lizard. A short local feature looks at how the Gila monster led researchers to GLP-1 medicines.
Healio
At the Cardiometabolic Health Congress, the UAB professor asked whether maximal weight loss is optimal and flagged that most non-diabetic patients quit GLP-1s within two years.
Ascletis says its lead amylin tablet ASC36o lasted about 7 days in monkeys and is now in a US Phase I study, with human PK data expected by the end of 2026.
ResearchAndMarkets puts the skincare peptide market at $0.95 billion in 2025, with anti-aging leading and haircare and personalized skincare growing fastest.
Loading…